These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12477049

  • 1. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ.
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS, Patel SR.
    J Exp Clin Cancer Res; 2009 Jun 06; 28(1):76. PubMed ID: 19500405
    [Abstract] [Full Text] [Related]

  • 3. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
    Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG.
    J Nucl Med; 2012 Feb 06; 53(2):275-80. PubMed ID: 22302964
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Ricciardi S, Del Tacca M, Danesi R.
    Pharmacol Res; 2007 Apr 06; 55(4):343-9. PubMed ID: 17296311
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K, Zhang Z, Bai Z, Ma X, Guo W, Wang Y.
    Oncol Rep; 2011 Apr 06; 25(4):963-70. PubMed ID: 21225236
    [Abstract] [Full Text] [Related]

  • 6. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, Talianidis I, Peters GJ.
    Biochem Pharmacol; 2004 Aug 15; 68(4):601-9. PubMed ID: 15276067
    [Abstract] [Full Text] [Related]

  • 7. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M.
    Neoplasia; 2010 Oct 15; 12(10):807-17. PubMed ID: 20927319
    [Abstract] [Full Text] [Related]

  • 8. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
    Sigmond J, Kroep JR, Loves W, Codacci-Pisanelli G, Peters GJ.
    Cancer Lett; 2004 Sep 30; 213(2):173-9. PubMed ID: 15327832
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
    Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y.
    Clin Cancer Res; 2005 May 01; 11(9):3485-93. PubMed ID: 15867251
    [Abstract] [Full Text] [Related]

  • 10. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ.
    Semin Oncol; 1995 Aug 01; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.
    Drug Metab Dispos; 2013 Mar 01; 41(3):541-5. PubMed ID: 23230131
    [Abstract] [Full Text] [Related]

  • 12. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
    Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM.
    Clin Cancer Res; 2001 Oct 01; 7(10):3263-8. PubMed ID: 11595723
    [Abstract] [Full Text] [Related]

  • 13. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY, Laliberté J, Momparler RL.
    Biochem Pharmacol; 1993 May 05; 45(9):1857-61. PubMed ID: 8494545
    [Abstract] [Full Text] [Related]

  • 14. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
    Ruiz van Haperen VW, Veerman G, Braakhuis BJ, Vermorken JB, Boven E, Leyva A, Peters GJ.
    Eur J Cancer; 1993 May 05; 29A(15):2132-7. PubMed ID: 8297652
    [Abstract] [Full Text] [Related]

  • 15. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ, Wang WX, Lin L, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2010 Jan 05; 32(1):17-21. PubMed ID: 20211060
    [Abstract] [Full Text] [Related]

  • 16. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R.
    Cancer Sci; 2004 Sep 05; 95(9):753-7. PubMed ID: 15471562
    [Abstract] [Full Text] [Related]

  • 17. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
    Cancer Chemother Pharmacol; 2010 Mar 05; 65(4):679-86. PubMed ID: 19639316
    [Abstract] [Full Text] [Related]

  • 18. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G.
    Biochem Pharmacol; 1996 Apr 12; 51(7):911-8. PubMed ID: 8651941
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA.
    Clin Cancer Res; 2006 Apr 15; 12(8):2492-7. PubMed ID: 16638857
    [Abstract] [Full Text] [Related]

  • 20. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR, van Moorsel CJ, Veerman G, Voorn DA, Schultz RM, Worzalla JF, Tanzer LR, Merriman RL, Pinedo HM, Peters GJ.
    Adv Exp Med Biol; 1998 Apr 15; 431():657-60. PubMed ID: 9598147
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.